| |
 |
Hyundai is your best choice as a trusted partner to help your business get a
rapid and efficient entry into the Korean market and achieve a stable settlement.
Hyundai has outstanding professional teams that are considered the most
experienced in clinical trials, regulatory affairs, and marketing in Korea.
The goal of Hyundai is to make significant scientific contributions, and to be a
recognized performance leader in the domestic market where we provide
innovative and valuable drugs to patients.
Hyundai accomplished fast market penetration of licensed products by
conducting multinational trials simultaneously with licensors.
Hyundai offers its partners various business options such as co-marketing, copromotion, joint-ventures and equity investment, and is open to exploring
value-adding partnerships in a broad range of cooperation.
Following therapeutic areas are targets that Hyundai is actively seeking and
focusing on:
- Cardiovascular disorder such as hypertension
- Endocrinology disorder such as Type I, II Diabetes & Diabetic complications
- CNS disorder such as Depression, Schizophrenia, Anxiety disorder, Insomnia, Alzheimer's disease, Parkinson's disease and Various pain types
- Ophthalmic disorder
- Respiratory disorder
- Oncology disorder
- Degenerative/Age-related diseases
If you have a potential partnering opportunity to discuss with Hyundai, please
email (BD@hdpharm.co.kr)
|
 |
|
YEAR |
EVENT |
2023 |
Janssen Korea
Exclusive Distribution and Promotion Agreement for Topamax, a medicine to treat epilepsy and migraine
|
2022 |
ASKA Pharmaceutical
Exclusive License and Supply Agreement for Slinda, an estrogen-free progestin only oral contraceptive
|
2020 |
Linepharma International
Exclusive Marketing and Distribution Agreement for Mifegymiso,
a combination product for the medical termination of a
pregnancy
Ferring Pharmaceuticals Korea
Co-Promotion Agreement for three women’s health products (Tractocile Injection, Duratocin RTS Injection, Propess Vaginal SR Tablet)
Sandoz Korea
Co-Promotion Agreement for three anti-depressant products (Escitalopram Tablet, Sertraline Tablet, Paroxetine Tablet)
|
2019 |
NEUROCHLORE (France)
Exclusive License Agreement for the Autism Spectrum Disorder treatment candidate
Seoul Saint Mary’s Hospital & KRICT (Korea)
Exclusive License Agreement for the “Composition for Hardening Soft Tissue”
BAUSCH & LOMB (USA)
Exclusive Distribution Agreement for Emerade, an adrenaline auto-injector for anaphylaxis
|
2018 |
MITHRA Pharmaceuticals (Belgium)
Exclusive License and Supply Agreement for Estelle, a novel combined oral contraceptive (COC) product candidate
|
2016 |
ACERUS Pharmaceuticals (Canada)
Exclusive License and Supply Agreement for Natesto, a testosterone nasal gel for replacement therapy in adult males
|
2015 |
ASLAN Pharmaceuticals (Singapore)
Collaboration and License Agreement for ASLAN001 (Varlitinib), a drug candidate for the treatment of advanced biliary tract cancer
Takeda Korea
Exclusive Distribution Agreement for Tachosil (Pre-rolled), a dual action surgical hemostatic patch
CHEMO (Spain)
Exclusive License and Supply Agreement for Lania (Levonorgestrel, Ethinyl Estradiol), a generic combined oral contraceptive (COC) product
Pfizer Korea
Co-Promotion Agreement for Duavive, a product for menopausal
hormone therapy (MHT)
Abbott Korea
Co-Promotion Agreement for Hokunalin Patch, a treatment of relief of various symptoms, such as dyspnea, resulting from airway obstruction in bronchial asthma, acute bronchitis, chronic bronchitis, and pulmonary emphysema
|
2014 |
DUCHESNAY (Canada)
Exclusive License and Supply Agreement for Dicletin, a product for
treating nausea and vomiting in pregnancy
CHEMO (Spain)
Exclusive License and Supply Agreement for Bonita (Desogestrel, Ethinyl Estradiol), a generic combined oral contraceptive (COC) product
|
2012 |
Takeda Korea
Exclusive Distribution Agreement for Tachosil, a dual action surgical hemostatic patch
|
2011 |
Bausch & Lomb South Asia Inc.
Co-Promotion Agreement for Ocuvite, an eye vitamin and mineral
supplements with Lutein
Ophtecs (Japan)
Exclusive License and Supply Agreement for Ruping, a preservativefree artificial tear
|
|
|
